The macro count is pretty clear. We're below the 38.2% fib of the impulsive move from the covid lows, and approaching the 50% fib as well as the bottom of the channel. The weekly RSI is lower then even the covid lows of march 2020. In fact the RSI hasn't been this low since inception in 2016.
As with all of ARK's ETF's these are long term plays. If you want biotech exposure, this is a great time to buy this ETF.
Ask yourself, do you think the healthcare industry is likely to be more profitable over the next 5 years or less profitable? Do you think innovations in gene editing, DNA sequencing and mRNA technology is going to increase or have we peaked in this era of perpetual covid?